Abstract
Anticancer drug resistance remains a significant challenge in cancer therapy, impeding the effectiveness of conventional chemotherapeutic agents. This resistance can occur through various mechanisms, including drug efflux, altered drug targets, and evasion of apoptosis. This article reviews the pharmacological mechanisms behind anticancer drug resistance, focusing on cellular and molecular pathways that facilitate resistance. It also discusses recent therapeutic strategies to overcome resistance, including combination therapies, molecular targeting, and immune modulation. Understanding the molecular underpinnings of drug resistance is crucial for the development of novel therapeutic interventions that can improve patient outcomes.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.